Fullerenemalonates inhibit amyloid beta aggregation, <i>in vitro</i> and <i>in silico</i> evaluation

Melchor Martínez‐Herrera, Susana Figueroa-Gerstenmaier, Francisco García‐Sierra, H.I. Beltrán, Norma Rivera-Fernández, Jorge A. Lerma Romero, López-Camacho Perla Y., Gustavo Basurto‐Islas

RSC Advances · 2018 · 24 citations · 60 references

DOIFull text

Open access

Concepts

Abstract

peptide. These data suggest that fullerenemalonates require specific substituents designed as sodium salt molecules to inhibit Aβ fibrillization and perform with low toxicity. These are promising molecules for developing future therapies involving Aβ aggregates in diseases such as AD and other types of dementia.

References

60